(secondQuint)ORBERA Post-Approval Study.

 FDA post-approval study designed to demonstrate the safety and effectiveness of ORBERA cent as an adjunct to weight reduction for obese adults (22 years of age and older) with a Body Mass Index (BMI) of 30 kg/m2 and BMI 40 kg/m2.

 Behavioral modification program in conjunction with endoscopic placement of a single ORBERA cent Intragastric Balloon, filled with saline to an inflation volume between 400cc and 700cc, for 26 weeks followed by endoscopic ORBERA cent removal.

 Outcomes include the mean percent Total Body Weight Loss (%TBWL), changes in weight, device and procedure-related AEs and SAEs: gastric ulcers, esophageal injury, placement and removal related SAEs, early device removals, and balloon deflations.

.

 ORBERA Post-Approval Study@highlight

A prospective, multicenter, open-label, post-approval study of the safety and effectiveness of ORBERA cent as an adjunct to weight reduction for obese adults (22 years of age and older) with a Body Mass Index (BMI) of 30 kg/m2 and BMI 40 kg/m2